The Baker Institute says the installation of next-generation proteomics and multi-omics technology this month will provide insights into cardiovascular biology, cell signalling and human health, supporting its researchers to accelerate the understanding of human cardiovascular health and disease.
It said applying the Thermo Scientific Orbitrap Astral Mass Spectrometer, which is unique in the cardiovascular health and disease space, will provide a high-throughput approach to translational research. It said the mass spectrometry-based technology adds to its expanding research profile in proteomics, developed over the past several years by Professor David Greening.
Professor Greening, an Amelia Hains Fellow, Head of Molecular Proteomics at the Baker Institute, and Director of the Proteomics and Metabolomics Platform at La Trobe University, is recognised as a leader in proteomics and cell signalling.
Professor Greening said “mass spectrometry-based omics technology has been a game-changer for systems biology, in terms of how we integrate and understand complex human biology and dynamic changes in health and disease."
“Continuing our strong track record of impact innovation, this remarkable advancement will enable our teams and networks to decipher this complexity at scale, to resolve and accelerate the discovery of proteins, their variants and advance precision medicine,” he said.
“This technology will also further advance our understanding of the mechanisms of ageing, organ circuitry, and cell and organ signalling.
“Importantly, the Thermo Scientific Orbitrap Astral Mass Spectrometer, in combination with advances in ionisation and quantitative resolution, and enhanced analysis throughput, overcomes key challenges in proteomics to enable the analysis of large cohorts, powering the study of proteomics at a scale previously only obtainable by genomics.”
The technology can be harnessed to address large-scale studies addressing critical areas of need, such as early detection and diagnostic profiling in heart health and development and refined cardiac disease remodelling. It also provides a roadmap for developing improved risk stratification and novel and specific therapies to prevent, diagnose and treat heart disease, diabetes and related diseases.
Thermo Fisher Scientific’s Vice President and General Manager, Australia and New Zealand, Domenic Stranieri, said that the collaboration with the Baker Heart and Diabetes Institute will help bridge the gap to a future less burderned by the affliction of heart disease and related conditions.
“We very much value the relationship we have with the Baker Institute and the pivotal role they play in the global search for novel and personalised methods to diagnose, treat, predict, and ultimately, prevent some of the greatest health challenges of current and past generations: cardiovascular disease, diabetes and other related degenerative conditions,” said Mr Stranieri. “By bringing together the Baker Institute’s almost 100 years of experience and knowledge, with the very latest innovation in mass spectrometry, we’re accelerating science and paving the way for the next wave of game changing breakthroughs.”